In a bid to expand capacity and upgrade manufacturing facilities, Syngene International is planning to invest $200 million over the next two years.
The investment areas for the capital expenditure are research centre, formulation centre, manufacturing facilities and expansion of new capabilities. The company will tap a mixture of its own resources and debt to raise funds for future growth. Future funding requirements will be met through internal accruals and debt.
Syngene International offers discovery and development services for novel molecular entities (NMEs) across industrial sectors including pharmaceutical, biotechnology, agrochemicals, consumer health, animal health, cosmetic and nutrition.
